February 13, 2025 Experience Eli Lilly $6.5 billion notes offering The investment-grade notes are due 2028, 2030, 2032, 2035, 2055 and 2065
February 7, 2025 Experience GH Research $150 million follow-on offering We advised GH Research on the offering of shares
January 28, 2025 Experience Ascentage Pharma $126.4 million IPO The IPO is the first life sciences U.S. IPO of 2025 and the first life sciences company listed on the HKEX to complete a U.S. listing
December 31, 2024 Experience Precigen $79 million preferred stock and warrants offering We advised Precigen on the private placement
December 16, 2024 Experience Ormat Technologies $282 million secondary offering The stock is listed on the NYSE and Tel Aviv Stock Exchange
December 16, 2024 Experience Sabre $800 million exchange offer and $775 million term loan exchange We are advising Sabre on the exchange offers
December 9, 2024 Experience Enviva emerges from chapter 11 We advised an ad hoc group of creditors in connection with Enviva’s chapter 11 proceedings
November 26, 2024 Experience Spirit Airlines prearranged chapter 11 filing We are advising Spirit Airlines in connection with entry into an RSA and negotiation of a prearranged chapter 11 plan
October 31, 2024 Experience Molecular Partners $20 million follow-on offering The ADSs are listed on the Nasdaq Global Select Market
October 18, 2024 Experience Inventiva private placement of up to €348 million The offering includes ordinary shares, pre-funded warrants and warrants